Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis
Related Experiment Video
Updated: Mar 2, 2026
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
969
Dinesh Khanna1, Daniel E Furst2, Philip J Clements2
1University of Michigan Scleroderma Program, Ann Arbor, MI, USA.
Journal of Scleroderma and Related Disorders
|May 19, 2017
Abstract:
The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic sclerosis (scleroderma). This state-of-art review provides a historical perspective of the development of the mRSS, summarizes the performance of mRSS as an outcome measure, provides guidance on assessing mRSS, and makes recommendations for incorporation of the mRSS into clinical trials.
